Calithera Biosciences Company Profile (NASDAQ:CALA)

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Calithera Biosciences Inc (NASDAQ:CALA) released its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.14. The company had revenue of $4.19 million for the quarter, compared to analysts' expectations of $1.40 million. View Calithera Biosciences' Earnings History.

4 brokers have issued 1 year target prices for Calithera Biosciences' stock. Their predictions range from $5.00 to $16.00. On average, they anticipate Calithera Biosciences' stock price to reach $11.75 in the next year. View Analyst Ratings for Calithera Biosciences.

Here are some recent quotes from research analysts about Calithera Biosciences stock:

• 1. According to Zacks Investment Research, "Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company's lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California. " (5/12/2017)
• 2. JMP Securities analysts commented, "Calithera Biosciences reports achievement of PK and PD goals in the Phase I trial of CB-1158, which entitles the company to receive a $12MM milestone payment as per its collaboration agreement with Incyte (INCY, MO, PT UR, Bayko); reiterate our Market Outperform rating and $12 price target based on a synthesis of our DCF, SOTP, and comparable company valuation methodologies. We view this early milestone achievement as further validation of the company's collaboration with INCY as well as of the subject of the agreement, CB-1158, a first-in-class arginase inhibitor and potential immunotherapeutic. CB-1158 has thus far demonstrated favorable pharmacologic activity in human subjects, with elevated plasma arginine levels consistent with those seen in preclinical cancer models. We remind investors that additional clinical data for CB-1158 in the setting of immuno-oncology are expected in mid-2017." (3/28/2017)

Calithera Biosciences saw a drop in short interest during the month of April. As of April 28th, there was short interest totalling 743,060 shares, a drop of 52.8% from the April 13th total of 1,575,180 shares. Based on an average trading volume of 413,042 shares, the short-interest ratio is presently 1.8 days. Currently, 2.8% of the company's stock are sold short.

Some companies that are related to Calithera Biosciences include Coherus Biosciences (CHRS), Insys Therapeutics (INSY), Insmed Incorporated (INSM), Xencor (XNCR), Acceleron Pharma (XLRN), Forward Pharma A/S (FWP), Epizyme (EPZM), Aimmune Therapeutics (AIMT), Cellectis SA (CLLS), Immunomedics (IMMU), ZIOPHARM Oncology (ZIOP), Alder Biopharmaceuticals (ALDR), Five Prime Therapeutics (FPRX), Ascendis Pharma A/S (ASND), Albany Molecular Research (AMRI), Achaogen (AKAO), TG Therapeutics (TGTX) and Esperion Therapeutics (ESPR).

Calithera Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (15.01%), FMR LLC (5.33%), Vanguard Group Inc. (3.37%), RA Capital Management LLC (2.05%), Bogle Investment Management L P DE (1.81%) and Monashee Investment Management LLC (1.20%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp Llc, Adage Capital Partners Gp, LL and Curtis Hecht. View Institutional Ownership Trends for Calithera Biosciences.

Calithera Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Franklin Street Advisors Inc. NC and Oxford Asset Management. View Insider Buying and Selling for Calithera Biosciences.

Calithera Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, FMR LLC, RA Capital Management LLC, Bogle Investment Management L P DE, Vanguard Group Inc., Monashee Investment Management LLC, Candriam Luxembourg S.C.A. and Goldman Sachs Group Inc.. Company insiders that have bought Calithera Biosciences stock in the last two years include Adage Capital Partners Gp Llc and Adage Capital Partners Gp, LL. View Insider Buying and Selling for Calithera Biosciences.

Shares of Calithera Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Calithera Biosciences stock can currently be purchased for approximately $15.90.